Bank Of America Corp Enlivex Therapeutics Ltd. Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.29 - $2.92 $737 - $1,670	-572 Reduced 68.26%	266 $0
Q1 2023 May 12, 2023	BUY	$3.41 - $4.55 $651 - $869	191 Added 29.52%	838 $3,000
Q4 2022 Feb 10, 2023	SELL	$3.74 - $4.81 $385 - $495	-103 Reduced 13.73%	647 $2,000
Q3 2022 Nov 14, 2022	SELL	$4.11 - $5.87 $1,911 - $2,729	-465 Reduced 38.27%	750 $3,000
Q2 2022 Aug 12, 2022	SELL	$3.81 - $8.64 $18,851 - $42,750	-4,948 Reduced 80.29%	1,215 $5,000
Q1 2022 May 16, 2022	BUY	$4.92 - $6.66 $14,105 - $19,094	2,867 Added 86.98%	6,163 $34,000
Q4 2021 Feb 08, 2022	SELL	$5.81 - $9.73 $2,260 - $3,784	-389 Reduced 10.56%	3,296 $21,000
Q3 2021 Nov 15, 2021	BUY	$7.43 - $13.86 $20,714 - $38,641	2,788 Added 310.81%	3,685 $36,000
Q2 2021 Sep 13, 2021	BUY	$8.61 - $12.1 $7,723 - $10,853	897 New	897 $8,000

2.1M

16.1K

3.4K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $28.9M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.